BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 16958961)

  • 1. The impact of HER-2 status on local recurrence in women with stage I-II breast cancer treated with breast-conserving therapy.
    Harris EE; Hwang WT; Lee EA; Cengel KA; Feldman MD; Demichele A; Kao G; Solin LJ
    Breast J; 2006; 12(5):431-6. PubMed ID: 16958961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression and possible prognostic role of MAGE-A4, NY-ESO-1, and HER-2 antigens in women with relapsing invasive ductal breast cancer: retrospective immunohistochemical study.
    Bandić D; Juretić A; Sarcević B; Separović V; Kujundzić-Tiljak M; Hudolin T; Spagnoli GC; Cović D; Samija M
    Croat Med J; 2006 Feb; 47(1):32-41. PubMed ID: 16489695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy.
    Nguyen PL; Taghian AG; Katz MS; Niemierko A; Abi Raad RF; Boon WL; Bellon JR; Wong JS; Smith BL; Harris JR
    J Clin Oncol; 2008 May; 26(14):2373-8. PubMed ID: 18413639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Yale University experience of early-stage invasive lobular carcinoma (ILC) and invasive ductal carcinoma (IDC) treated with breast conservation treatment (BCT): analysis of clinical-pathologic features, long-term outcomes, and molecular expression of COX-2, Bcl-2, and p53 as a function of histology.
    Moran MS; Yang Q; Haffty BG
    Breast J; 2009; 15(6):571-8. PubMed ID: 19995377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improving local control with breast-conserving therapy: a 27-year single-institution experience.
    Cabioglu N; Hunt KK; Buchholz TA; Mirza N; Singletary SE; Kuerer HM; Babiera GV; Ames FC; Sahin AA; Meric-Bernstam F
    Cancer; 2005 Jul; 104(1):20-9. PubMed ID: 15912514
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group.
    Kyndi M; Sørensen FB; Knudsen H; Overgaard M; Nielsen HM; Overgaard J;
    J Clin Oncol; 2008 Mar; 26(9):1419-26. PubMed ID: 18285604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular predictive factors for local recurrence and distant metastasis of breast cancer after lumpectomy with postoperative radiation therapy.
    Amornmarn R; Bui MM; Prempree TB; Masood S
    Ann Clin Lab Sci; 2000 Jan; 30(1):33-40. PubMed ID: 10678581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation of clinical, pathological status, hormone receptor and C-erbB-2 oncoprotein in breast cancer patients.
    Aryandono T; Harijadi ; Ghozali A
    Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():600-6. PubMed ID: 10895217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The association between biological subtype and locoregional recurrence in newly diagnosed breast cancer.
    Gabos Z; Thoms J; Ghosh S; Hanson J; Deschênes J; Sabri S; Abdulkarim B
    Breast Cancer Res Treat; 2010 Nov; 124(1):187-94. PubMed ID: 20814819
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Her-2 Neu overexpression on outcome of elderly women treated with wide local excision and breast irradiation for early stage breast cancer: an exploratory analysis.
    Poltinnikov IM; Rudoler SB; Tymofyeyev Y; Kennedy J; Anne PR; Curran WJ
    Am J Clin Oncol; 2006 Feb; 29(1):71-9. PubMed ID: 16462507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of lobular carcinoma in situ in association with invasive breast cancer on the rate of local recurrence in patients with early-stage breast cancer treated with breast-conserving therapy.
    Jolly S; Kestin LL; Goldstein NS; Vicini FA
    Int J Radiat Oncol Biol Phys; 2006 Oct; 66(2):365-71. PubMed ID: 16965988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High prevalence of HER-2/neu overexpression among Iranian women with breast cancer: true or false?
    Saatee S; Afrakhteh M; Sadrolhefazi B
    Breast J; 2006; 12(5):499-501. PubMed ID: 16958978
    [No Abstract]   [Full Text] [Related]  

  • 14. Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel.
    Millar EK; Graham PH; O'Toole SA; McNeil CM; Browne L; Morey AL; Eggleton S; Beretov J; Theocharous C; Capp A; Nasser E; Kearsley JH; Delaney G; Papadatos G; Fox C; Sutherland RL
    J Clin Oncol; 2009 Oct; 27(28):4701-8. PubMed ID: 19720911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Combined surgery and radiotherapy in the treatment of ductal carcinoma in situ of the breast: preliminary results of the Hungarian multicenter prospective randomised study].
    Polgár C; Orosz Z; Kahán Z; Gábor G; Jani N; Cserni G; Hadijev J; Kulka J; Sulyok Z; Boross G; Lázár G; László Z; Diczházi C; Udvarhelyi N; Szabó E; Péntek Z; Major T; Fodor J
    Magy Onkol; 2008 Sep; 52(3):269-77. PubMed ID: 18845497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The receptor expression pattern in ductal carcinoma in situ predicts recurrence.
    Kepple J; Henry-Tillman RS; Klimberg VS; Layeeque R; Siegel E; Westbrook K; Korourian S
    Am J Surg; 2006 Jul; 192(1):68-71. PubMed ID: 16769278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Results with accelerated partial breast irradiation in terms of estrogen receptor, progesterone receptor, and human growth factor receptor 2 status.
    Wilder RB; Curcio LD; Khanijou RK; Eisner ME; Kakkis JL; Chittenden L; Agustin J; Lizarde J; Mesa AV; Macedo JC; Ravera J; Tokita KM
    Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):799-803. PubMed ID: 20869583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is breast conservation therapy a viable option for patients with triple-receptor negative breast cancer?
    Parker CC; Ampil F; Burton G; Li BD; Chu QD
    Surgery; 2010 Aug; 148(2):386-91. PubMed ID: 20580045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of external boost volume in breast-conserving therapy on local control with long-term follow-up.
    Jobsen JJ; van der Palen J; Ong F
    Int J Radiat Oncol Biol Phys; 2008 May; 71(1):115-22. PubMed ID: 18234450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Breast-conservation treatment for early invasive breast cancer: prognostic factors for survival after salvage treatment of local recurrence].
    Fodor J
    Magy Onkol; 2007; 51(2):127-31. PubMed ID: 17660868
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.